InSilico Medicine Announces Major Global Pipeline Licensing and AI Drug Discovery Collaboration with Eli Lilly

Key Highlights for Investors

• Strategic Collaboration: InSilico Medicine Cayman TopCo (“Insilico Medicine”) has entered into a landmark licensing and drug discovery collaboration with global pharmaceutical leader Eli Lilly and Company (“Lilly”).
• Exclusive License: The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialization of potentially best-in-class, novel oral therapeutics currently in preclinical development. These therapeutics target specific indications, details of which may be highly relevant to Lilly’s portfolio expansion.
• AI-Driven Innovation: The collaboration leverages Insilico Medicine’s proprietary AI engine and “Pharma.AI” platforms to accelerate drug discovery and development across multiple therapeutic areas. This partnership combines Insilico’s AI and automation technologies with Lilly’s extensive development capabilities and disease-area expertise.
• Financial Structure: Insilico Medicine will receive a substantial upfront payment of USD 115 million. Further, the agreement includes development, regulatory, and commercial milestone payments, potentially raising the total deal value to approximately USD 2.75 billion. Tiered royalties on future sales will also be paid to Insilico Medicine.
• R&D Collaboration: Insilico Medicine and Lilly will jointly work on multiple R&D programs, focused on targets selected by Lilly, further integrating AI-driven solutions into Lilly’s pipeline.
• Company Profile: Insilico Medicine is a pioneering global biotech firm, listed on the Hong Kong Stock Exchange (stock code: 03696.HK), specializing in integrating AI and automation in drug discovery. The company’s capabilities extend to fibrosis, oncology, immunology, pain, obesity, and metabolic disorders, as well as applications in advanced materials, agriculture, nutrition, and veterinary medicine.
• Potential Price Sensitivity: The announcement of this high-value, global collaboration, with significant upfront and milestone payments, is likely to be price sensitive and could materially affect Insilico Medicine’s share value. Investors should consider the implications of the deal’s scale, exclusivity, and technological impact.

Details for Shareholders and Potential Investors

The collaboration with Lilly signals a major validation of Insilico Medicine’s AI drug discovery platform and marks a significant step in its global expansion strategy. The exclusive worldwide license granted to Lilly covers novel oral therapeutics, which are currently in the preclinical stage, targeting specific disease indications. This exclusivity, combined with joint R&D efforts, underscores the strategic importance of the partnership and the value of Insilico’s intellectual property.

The financial terms are particularly noteworthy: an upfront payment of USD 115 million, with further milestone payments that could bring the total deal value to USD 2.75 billion. The addition of tiered royalties on future sales provides Insilico Medicine with long-term revenue potential, contingent on successful clinical development and commercialization by Lilly.

Insilico Medicine’s AI-driven platform, Pharma.AI, is recognized for its ability to accelerate drug discovery, reduce development timelines, and address unmet medical needs in areas such as fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. The company’s broad reach into adjacent industries also signals its potential for future diversification and innovation.

The board stresses that neither the financial data nor the forward-looking statements in this announcement have been audited or reviewed by external auditors. Investors are urged to exercise caution and not place excessive reliance on the projections or unaudited figures disclosed.

Governance and Leadership

As of the announcement date (March 29, 2026), Insilico Medicine’s board comprises experienced executives and directors, including Chairman, CEO, and CBO Mr. Aleksandrs Zavoronkovs, Ph.D., alongside other executive, non-executive, and independent non-executive directors, all with strong academic and industry backgrounds.

Conclusion

This collaboration represents a transformative milestone for Insilico Medicine, validating its AI-powered drug discovery platform, securing substantial upfront and milestone payments, and opening the door for long-term royalty streams. The exclusivity and global scope of the agreement with Lilly are likely to have a significant impact on the company’s future growth and share value. Investors should monitor further developments as the partnership progresses and clinical milestones are met.

Disclaimer

The contents of this article are based on publicly disclosed information and forward-looking statements, which may or may not be attainable or realized. The financial data provided has not been audited and should not be relied upon for investment decisions. Investors are strongly advised to exercise caution, conduct their own research, and seek professional advice before making any investment in Insilico Medicine or related securities.

View INSILICO Historical chart here